NASDAQ:MOR

MorphoSys (MOR) Stock Price, News & Analysis

MorphoSys logo
$18.96 0.00 (0.00%)
As of 11/6/2026

About MorphoSys Stock (NASDAQ:MOR)

Advanced

Key Stats

Today's Range
$18.96
▼
$18.96
50-Day Range
$18.96
▼
$18.96
52-Week Range
$4.18
▼
$19.50
Volume
N/A
Average Volume
1.02 million shs
Market Capitalization
$2.86 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

MorphoSys AG was a German biopharmaceutical company focused on developing medicines for cancer and other serious diseases. Founded in 1992 and headquartered in Planegg, near Munich, it built antibody-discovery technologies and developed a pipeline of antibody-based treatments and other therapies.

Its best-known product was tafasitamab, marketed in the United States as Monjuvi and in Europe as Minjuvi. MorphoSys developed the treatment with Incyte for certain adults with diffuse large B-cell lymphoma. The company also advanced pelabresib, an investigational treatment for myelofibrosis, and worked with research and commercial partners in markets including the United States and Europe.

Novartis completed its acquisition of MorphoSys in 2024. MorphoSys is therefore no longer an independent publicly traded company; its former Nasdaq symbol was MOR.

AI Generated. May Contain Errors.

Receive MOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MorphoSys and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MOR Stock News Headlines

Morphosys AG : MOR
I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
See More Headlines

MOR Stock Analysis - Frequently Asked Questions

MorphoSys' stock was trading at $18.96 at the beginning of the year. Since then, MOR stock has increased by 0.0% and is now trading at $18.96.

MorphoSys (MOR) raised $200 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 8,300,000 shares at a price of $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners acted as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that MorphoSys investors own include Bristol Myers Squibb (BMY), Visa (V), Amarin (AMRN), Gilead Sciences (GILD), AbbVie (ABBV), Salesforce (CRM) and Walt Disney (DIS).

Company Calendar

Today
11/16/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:MOR
CIK
1340243
Employees
730
Year Founded
1992

Profitability

EPS (Trailing Twelve Months)
($3.48)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$205.35 million
Net Margins
-226.79%
Pretax Margin
-225.77%
Return on Equity
-694.31%
Return on Assets
-22.55%

Debt

Debt-to-Equity Ratio
4.98
Current Ratio
1.38
Quick Ratio
1.38

Sales & Book Value

Annual Sales
$238.28 million
Price / Sales
11.99
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.35 per share
Price / Book
54.17

Miscellaneous

Outstanding Shares
150,621,000
Free Float
150,546,000
Market Cap
$2.86 billion
Optionable
No Data
Beta
1.20

Social Links

The 7 Best High-Yield Dividend Stocks for 2027 Cover

Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.

Get This Free Report

This page (NASDAQ:MOR) was last updated on 11/6/2026 by MarketBeat.com Staff.
From Our Partners